Physician profile
John Ho
NPI 1518963933
$10,946.14
in general payments reported to CMS, 2019-2025
54 companies · $1,893 in 2025
The $1,893 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,421 · 2020: $868 · 2021: $1,416 · 2022: $1,409 · 2023: $1,854 · 2024: $2,084 · 2025: $1,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,200.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,832.16 | 2020-2025 | |
| Lilly USA, LLC | $870.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $540.61 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $517.05 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $491.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $439.44 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $337.33 | 2023-2025 | Auvelity, Sunosi |
| Merck Sharp & Dohme LLC | $332.96 | 2019-2025 | Gardasil 9, Capvaxive, Lagevrio |
| Teva Pharmaceuticals USA, INC. | $297.03 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Idorsia Pharmaceuticals US INC | $233.78 | 2022-2024 | Quviviq |
| Neos Therapeutics, Lp | $228.47 | 2022-2025 | Adzenys Xr-Odt |
| Vivus LLC | $209.81 | 2019-2024 | Qsymia, Pancreaze |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.47 | 2021-2025 | Xifaxan, Trulance |
| Kowa Pharmaceuticals America, INC. | $172.62 | 2019-2025 | Zoryve, Livalo |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.